Piperacillin And Tazobactam 10 Ml In 1 Vial while Breastfeeding

For most of the drugs advantages of taking medications overweighs the potential risks however some drugs could be really dangerous for breastfed baby hence every medication shall be considered separately. In this page we will discuss about purpose of Piperacillin And Tazobactam 10 Ml In 1 Vial and its risk associated with lactation. We will also discuss the usage of Piperacillin And Tazobactam 10 Ml In 1 Vial and some common side effects associated with Piperacillin And Tazobactam 10 Ml In 1 Vial.

Piperacillin and tazobactam for injection, USP is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of: Intra-abdominal infections (1.1) Skin and skin structure infections (1.2) Female pelvic infections (1.3) Community-acquired pneumonia (1.4) Nosocomial pneumonia (1.5) Usage (1.6) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.6) Piperacillin and tazobactam for injection, USP is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a β-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the conditions listed below. 1.1 Intra-abdominal Infections Appendicitis (complicated by rupture or abscess) and peritonitis caused by β-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus. The individual members of this group were studied in fewer than 10 cases. 1.2 Skin and Skin Structure Infections Uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by β-lactamase producing isolates of Staphylococcus aureus. 1.3 Female Pelvic Infections Postpartum endometritis or pelvic inflammatory disease caused by β-lactamase producing isolates of Escherichia coli. 1.4 Community-acquired Pneumonia Community-acquired pneumonia (moderate severity only) caused by β-lactamase producing isolates of Haemophilus influenzae. 1.5 Nosocomial Pneumonia Nosocomial pneumonia (moderate to severe) caused by β-lactamase producing isolates of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2) ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and tazobactam for injection, USP and other antibacterial drugs, Piperacillin and tazobactam for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Statement of Manufacturer/Labeler about breastfeeding usage
8.2 Lactation Risk Summary Piperacillin is excreted in human milk; tazobactam concentrations in human milk have not been studied. No information is available on the effects of piperacillin and tazobactam on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for piperacillin and tazobactam for injection and any potential adverse effects on the breastfed child from piperacillin and tazobactam for injection or from the underlying maternal condition.